Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Granules"

96 News Found

Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq
Drug Approval | January 28, 2022

Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq

Potassium chloride is used to prevent or to treat low blood levels of potassium


Dr. K.V.S Ram Rao is the new JMD & CEO of Granules India
People | January 05, 2022

Dr. K.V.S Ram Rao is the new JMD & CEO of Granules India

He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management


Granules receives ANDA approval for amphetamine mixed salts
Drug Approval | December 30, 2021

Granules receives ANDA approval for amphetamine mixed salts

The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health


Granules Inc., receives ANDA approval for prazosin hydrochloride
Drug Approval | December 28, 2021

Granules Inc., receives ANDA approval for prazosin hydrochloride

The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health


Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director
People | December 24, 2021

Granules India appoints Sucharita Rao Palepu as Non-executive Independent Director

Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services


Granules gets ANDA approval for Dofetilide capsules
Drug Approval | October 18, 2021

Granules gets ANDA approval for Dofetilide capsules

The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm


Granules India recalls one batch of Naproxen Sodium 220mg tablets
News | September 13, 2021

Granules India recalls one batch of Naproxen Sodium 220mg tablets

One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled


Granules India receive DRDO licence to manufacture and market 2-DG
News | September 02, 2021

Granules India receive DRDO licence to manufacture and market 2-DG

The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19


Granules India receives approval from Health Canada for arthritis drug
News | August 30, 2021

Granules India receives approval from Health Canada for arthritis drug

Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.